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ABSTRACT
Wolf-Hirschhorn syndrome (WHS) represents an archetypical
example of a contiguous gene deletion disorder – a condition
comprising a complex set of developmental phenotypes with a
multigenic origin. Epileptic seizures, intellectual disability, growth
restriction, motor delay and hypotonia are major co-morbidities in
WHS. Haploinsufficiency of LETM1, which encodes a mitochondrial
inner-membrane protein functioning in ion transport, has been
proposed as an underlying pathomechanism, principally for seizures
but also for other core features of WHS, including growth and motor
delay. Growing evidence derived from several model organisms
suggests that reduced LETM1 expression is associated with some
element of mitochondrial dysfunction. Surprisingly, LETM1-dependent
mitochondrial functional deficits have not previously been described
in cells from individuals with WHS. Here, using a unique panel of
WHS-patient-derived cell lines with deletions of differing sizes,
incorporating LETM1 or not, we show, for the first time, that LETM1
expression is reduced in mitochondria isolated from WHS-patient
cells. Furthermore, we show that this is associated with distinct
mitochondrial phenotypes, including altered intracellular [Ca2+] levels,
dysfunctional mitochondrial transition-pore opening, hyperpolarization
and superoxide leakage from resting mitochondria. Interestingly, we
find that these phenotypes segregate with seizures in our WHS
cohort. Our findings identify novel cellular phenotypes in WHS
attributable to a 50% reduction in LETM1 expression level; these
phenotypes could underlie and/or contribute to some of the core
clinical features of this condition.
KEY WORDS: LETM1, Wolf-Hirschhorn syndrome, Mitochondria
INTRODUCTION
Wolf-Hirschhorn syndrome (WHS) is a contiguous gene deletion
disorder caused by hemizygous deletion within chromosome 4p16.3
(Bergemann et al., 2005; Hirschhorn, 2008). The core clinical
features of WHS consist of microcephaly, growth retardation,
intellectual disability, atrial and ventricular septal defects, skeletal
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abnormalities, a characteristic facial dysmorphology, hypotonia, and
epileptic seizures (Hirschhorn and Cooper, 1961; Hirschhorn et al.,
1965; Wolf et al., 1965). The spectrum and severity of these clinical
features typically correlate with deletion size (Battaglia et al., 2008;
Maas et al., 2008; Van Buggenhout et al., 2004; Zollino et al., 2000).
WHS is generally regarded as a multigenic disorder, although two
critical regions have been described: WHSCR1 and WHSCR2, for
WHS critical region 1 and 2, respectively (see Fig. 1). These critical
regions are based on the demarcation of the minimum region of
overlap in individuals exhibiting WHS-like phenotypes. WHSCR1
incorporates part of the WHS candidate gene WHSC1 and the entire
WHSC2 gene (White et al., 1995; Wright et al., 1997). WHSCR2
incorporates LETM1 and part of WHSC1 but not WHSC2
(Rodríguez et al., 2005; Zollino et al., 2003) (Fig. 1). It is thought
that haploinsufficiency of WHSC1 and WHSC2 accounts for many
of the core phenotypes in WHS.
WHSC1, also known as NSD2 (nuclear receptor SET domain
containing) and MMSET (multiple myeloma SET domain
containing), encodes a putative histone methyltransferase with
features of a transcriptional co-repressor (Kim et al., 2008; Marango
et al., 2008). WHSC1 (NSD2/MMSET) controls histone H3-
trimethylation on lysine-36 (H3-K36-me3), a modification
associated with actively transcribed regions (Li et al., 2009; Nimura
et al., 2009). WHSC2, also known as NELF-A, encodes a component
of the negative elongation factor (NELF) complex (Narita et al.,
2007). This complex induces promoter-proximal pausing by
inhibiting RNA polymerase II progression early during elongation,
thereby altering expression of its target genes in a positive and
negative manner (Chiba et al., 2010; Gilchrist et al., 2008).
Although haploinsufficiency of both WHSC1 and WHSC2 are
thought to underlie many of the core clinical features of WHS, other
genes additionally contribute to features such as facial
dysmorphology, microcephaly and growth retardation, reinforcing
the multigenic nature of this disorder (Engbers et al., 2009;
Hammond et al., 2012; Hannes et al., 2012; South et al., 2007; South
et al., 2008; Van Buggenhout et al., 2004). Untangling the complex
functional relationships between the various genes that are
haploinsufficient in WHS is essential to fully understand the
underlying pathophysiology of this condition.
Over 90% of WHS patients with haploinsufficiency of the typical
WHS critical regions exhibit severe generalised tonic-clonic
epileptic seizures within the first 3 years of life (Battaglia et al.,
2008; Battaglia et al., 2009). This represents a major clinical
challenge in these individuals (Battaglia and Carey, 1999). Although
generally improving with age, seizures can also be managed with
valproate and/or phenobarbital (Battaglia et al., 2009).
Haploinsufficiency of LETM1, which encodes the mitochondrial
protein leucine-zipper EF-hand-containing transmembrane protein
1 (LETM1), is thought to contribute to seizure development in WHS
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(Dimmer et al., 2008; Endele et al., 1999; Hasegawa and van der
Bliek, 2007; McQuibban et al., 2010; Nowikovsky et al., 2004;
Tamai et al., 2008). This contribution is largely based on precisely
defining the location and content of overlapping deletions in WHS
and WHS-like patients with and without seizures. Nevertheless,
there is additional evidence to suggest that other genes, aside from
LETM1, might also play a role in some cases (Andersen et al., 2013;
Misceo et al., 2012; South et al., 2007).
LETM1 is a highly attractive contributing candidate for seizures
in WHS principally because of its demonstrated role in various
aspects of mitochondrial homeostasis (Dimmer et al., 2008; Endele
et al., 1999; Hasegawa and van der Bliek, 2007; McQuibban et al.,
2010; Nowikovsky et al., 2004; Tamai et al., 2008). Impaired
mitochondrial function, abnormal ion-buffering and elevated
mitochondrially derived reactive oxygen species (ROS) are all
established interrelated pathomechanisms of seizures (Folbergrová
and Kunz, 2012; Kang et al., 2013). Reduced expression of LETM1
and its orthologues have variously been identified as impacting upon
mitochondrial morphology (increased swelling and elongation) and
consequently upon function by controlling K+/H+ ion exchange, and
also upon mitochondrial Ca2+ buffering by acting as a Ca2+/H+
antiporter (Jiang et al., 2009; Nowikovsky et al., 2012).
The precise role of LETM1 in mitochondrial ion transport is
currently an area of intense debate (Nowikovsky et al., 2012;
Nowikovsky et al., 2009). Nevertheless, recent studies modelling
reduced Letm1 expression in mice and rats demonstrated a reduced
threshold for chemically induced seizures (Jiang et al., 2013; Zhang
et al., 2013). Furthermore, in the Letm1 rat study, the authors
reported increased mitochondrial swelling and decreased
mitochondrial cytochrome b levels (Zhang et al., 2013). In the
mouse study, an associated impairment in mitochondrial Ca2+
buffering and consequent mitochondrial function were documented
in Letm1/− animals (Jiang et al., 2013).
Surprisingly, specific LETM1-dependent functional mitochondrial
defects have not been demonstrated previously in WHS-patient-
derived cell lines. In fact, in one study, although reduced LETM1
expression was observed in WHS-patient-derived fibroblasts, levels
were found to be unaffected in the corresponding patient
lymphoblastoid cell lines (LCLs) (Dimmer et al., 2008). Here, using
a unique panel of WHS-patient-derived LCLs from individuals with
deletions either incorporating LETM1 or not, we set out to identify
and characterise LETM1-dependent mitochondrial phenotypes.
RESULTS
The patient LCLs used in this study and their respective deletions
are shown in Fig. 1. All of these lines are derived from patients
previously described in the literature (Engbers et al., 2009; Hannes
et al., 2010; Maas et al., 2008; Rauch et al., 2001). Of note, FN4367
is an LCL derived from the patient described by Rauch and
colleagues involving one of the smallest deletions catalogued in
4p16.3 in a patient exhibiting mild WHS phenotypes, but without
seizures (Rauch et al., 2001). This is an interstitial 191.5 kb deletion
encompassing WHSCR1, and not involving LETM1 (Rauch et al.,
2001). LCL C(355) is from a WHS-like individual with a terminal
deletion up to and including SLBP, thereby preserving LETM1 and
the WHSCRs (Engbers et al., 2009; Hannes et al., 2010). This
individual has not presented with seizures (Engbers et al., 2009).
WHS-patient LCLs haploinsufficient for LETM1 exhibit
reduced LETM1 expression
Surprisingly, reduced LETM1 expression has not previously been
consistently and unequivocally demonstrated in WHS-patient-
derived cells despite LETM1 haploinsufficiency being proposed to
contribute to seizure development in this condition (Dimmer et al.,
2008; Hasegawa and van der Bliek, 2007). To conclusively address
this issue, we interrogated LETM1 expression in our cohort of
genomically characterised WHS and WHS-like patient LCLs. Using
urea-denatured whole-cell extracts (WCEs) prepared from our panel
of patient LCLs with and without deletions incorporating LETM1,
we found that haploinsufficiency of LETM1 is in fact associated
with an ~50% reduction in LETM1 expression (Fig. 2A,B). LCLs
derived from patients A(83), D(78) and E(88) all showed reduced
LETM1 expression associated with LETM1 haploinsufficiency. This
is in contrast to extracts prepared from C(355) and FN4367, two
lines with normal LETM1 copy number (Fig. 2A,B).
LETM1 protein resides in the inner mitochondrial membrane
(IMM) (Endele et al., 1999; Tamai et al., 2008). Considering our
results obtained using urea-denatured WCEs, we reasoned that
WHS-patient LCLs haploinsufficient for LETM1 would also exhibit
RESEARCH ARTICLE Disease Models & Mechanisms (2014) doi:10.1242/dmm.014464
TRANSLATIONAL IMPACT
Clinical issue
Wolf-Hirschhorn syndrome (WHS) is a genetic disorder that is caused by
contiguous hemizygous deletions (deletions that affect only one copy of
a chromosome pair) within chromosome 4p16.3. It is a complex disorder
but its core clinical features consist of microcephaly, growth restriction,
intellectual disability, cardiac and skeletal abnormalities, facial
dysmorphology, hypotonia and epileptic seizures. The presence of only
one functional copy of specific genes located in chromosome 4p16.3
(haploinsufficiency) has been implicated in the pathogenesis of this
condition. To fully understand WHS, it is necessary to untangle the
complex relationships between the size of the hemizygous deletion and
the spectrum and severity of the condition’s clinical features.
Haploinsufficiency of LETM1, which encodes a mitochondrial protein that
is involved in ion transport, is thought to underlie the seizures and some
other features of classical WHS, but how LETM1 haploinsufficiency
contributes to seizure presentation or indeed whether individuals with
WHS exhibit any LETM1-dependent phenotypes has not been fully
elucidated. 
Results
In this study, the authors use a unique panel of cell lines derived from
individuals with WHS to show that LETM1 expression is reduced in cell
extracts and mitochondria isolated from those with LETM1
haploinsufficiency. They catalogue several interdependent newly
identified mitochondrial phenotypes that are associated with reduced
LETM1 expression, including altered intracellular calcium levels,
dysfunctional mitochondrial transition pore opening, hyperpolarisation
and superoxide leakage. Using siRNA and cDNA transfection
approaches, they show that these phenotypes are a direct consequence
of reduced LETM1 expression. Finally, the authors report that the
LETM1-dependent mitochondrial phenotypes segregate with seizures in
the small cohort of patients from whom the cell lines were derived. 
Implications and future directions 
These findings provide the first direct evidence that cells with LETM1
haploinsufficiency obtained from individuals with WHS exhibit reduced
LETM1 expression and that mitochondrial dysfunction is a consequence
of the 50% reduction in LETM1 expression, thereby providing new
pathomechanistic insights into WHS. Although studies in mouse models
that have reduced Letm1 expression strongly suggest a link between
reduced Letm1 expression and seizures, recent work in individuals with
WHS suggests that LETM1 haploinsufficiency might also contribute to
growth restriction, feeding difficulties, and motor and speech delays; the
mitochondrial dysfunctions revealed here could conceivably contribute
to these other characteristic features of WHS. Finally, these novel
findings raise the possibility that mitochondrial-based therapeutic
interventions could be of benefit in the management of WHS and should
therefore be investigated. 
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reduced LETM1 expression in mitochondria. Using an anti-TOM22
affinity-based magnetic mitochondrial isolation system (Miltenyi
Biotech), we isolated intact mitochondria from each of our WHS-
patient LCLs. Similar to our results obtained from WCEs, we found
that mitochondrial extracts prepared from LCLs from patients with
LETM1 haploinsufficiency exhibited reduced LETM1 compared
with patient-derived LCLs with normal LETM1 copy number
(Fig. 2C,D). Therefore, we conclude that LETM1 haploinsufficiency
in the context of WHS is consistently associated with reduced
expression of LETM1 in mitochondria of patient LCLs.
In our patient cohort, reduced mitochondrial LETM1 expression
seems to segregate with seizure development. To try and understand
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Fig. 1. An ideogram of human somatic autosome (HSA) 4,
focusing on 4p16.3 and showing the relative positions of
the WHS critical regions WHSCR1 and WHSCR2. The
relative position of certain key genes within and adjacent to
these regions are also shown, with LETM1 highlighted in red.
The various LCLs used in this study are listed on the bottom
left-hand side adjacent to the dashed grey lines, which depict
the position and extent of their specific deletions. The vertical
red arrow is to denote which LCLs exhibit LETM1
haploinsufficiency and which do not. The LCLs A(83), D(78)
and E(88) are from patients described in Maas et al. (Maas et
al., 2008). Deletion sizes are: A(83), tel-3.85Mb; D(78), tel-
2.42Mb; and E(88), tel-2.161Mb. The LCL C(355) has a
terminal deletion up to and including SLBP and is clinically
described in Engbers et al. (Engbers et al., 2009), whereas
FN4367 is described in Rauch et al. (Rauch et al., 2001). tel,
telomere; cen, centromere.
Fig. 2. LETM1 expression in WHS-patient LCLs. (A) Urea-based whole cell extracts (WCEs) were titrated (2.5, 5, 10 μg) for each WHS-patient LCL and run
alongside those from wild-type (WT) control extracts from a normal individual and blotted for LETM1 expression. Membranes were re-probed for β-tubulin to
confirm loading. (B) LETM1 expression for each WHS cell line relative to WT were quantified (a.u., arbitrary units) using ImageJ software from scanned blots.
Each quantitation represents the mean ± s.d. from at least three separate determinations. Measurements were also taken directly from membranes during
enhanced chemiluminescence (ECL) development using the Image Quant LAS 4000 luminescent image analyser and analysed with Image Quant TL7.01
software, which yielded identical comparative changes as ImageJ processing. A(83), D(78) and E(88) exhibit reduced LEMT1 expression compared with WT,
C(355) and FN4367 (P<0.05, Student’s t-test). (C) Urea-extracts were prepared from anti-TOM22 affinity-isolated mitochondria using the Miltenyi Biotech
magnetic capture kit. Hexokinase expression, as a mitochondrial marker, is shown for each LCL. Different amounts of urea-mitochondrial extract was subjected
to western blot analysis for LETM1 expression. (D) Relative LETM1 expression of each line compared with WT were quantified using ImageJ software from
scanned blots as in B. Each quantitation represents the mean ± s.d. from at least three separate determinations. A(83), D(78) and E(88) exhibit reduced
LEMT1 expression compared with WT and C(355) (P<0.05, Student’s t-test). D
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whether we could link LETM1 expression levels with a specific
mitochondrial deficit or a set of deficits, we investigated different
aspects of mitochondrial function in these patient LCLs.
LETM1 haploinsufficiency in WHS does not affect
mitochondrial mass but is associated with elevated
intracellular [Ca2+]
Using MitoTracker-Green to determine mitochondrial mass, we
found that all of the WHS-patient LCLs exhibited a similar
mitochondrial content to each other, irrespective of LETM1 copy
number, and to LCLs from a normal wild-type (WT) control
(Fig. 3A). Therefore, haploinsufficiency of LETM1, although
resulting in reduced mitochondrial LETM1 expression, does not
seem to affect mitochondrial content within WHS-patient LCLs.
Mitochondria represent one of the key cellular Ca2+ buffering
systems within the cell (Osellame et al., 2012; Szabadkai and
Duchen, 2008). Because LETM1 has been described as a Ca2+/H+
antiporter, we investigated levels of intracellular Ca2+ using the
fluorescent long-wave Ca2+ indicator, Calcium 1-AM, in the context
of LETM1 haploinsufficiency (Jiang et al., 2009). Interestingly, we
found elevated levels of intracellular [Ca2+] in WHS-patient LCLs
with LETM1 haploinsufficiency [i.e. A(83), D(78) and E(88)],
compared with those with normal LETM1 copy number [i.e. C(355)
and FN4367], potentially suggestive of a problem in Ca2+ buffering
in these cells (Fig. 3B,C). This phenotype has not previously been
described in WHS-patient cells, but is consistent with reduced
mitochondrial Ca2+ uptake recently demonstrated in cells from a
Letm1/− mouse model (Jiang et al., 2013).
LETM1 haploinsufficiency in WHS is associated with
impaired mPTP dynamics
The mitochondrial permeability transition pore (mPTP) is a non-
selective voltage-dependent mitochondrial channel proposed to
reside in the IMM (Bernardi, 2013; Siemen and Ziemer, 2013).
Opening of the mPTP increases the permeability of the IMM to
solutes of >1.5 kDa in size. Under normal physiological
conditions, this pore flickers between an open and closed state.
However, various stimuli, such as elevated ROS levels and
increased levels of mitochondrial calcium, promote the sustained
opening of this pore. We investigated mPTP dynamics using the
MitoProbe Transition Pore Assay Kit (Invitrogen-MitoProbes),
which uses calcein fluorescence in the presence of CoCl2 as an
indicator of the retention of calcein within mitochondria when the
mPTP is in the closed state; CoCl2 quenches cytoplasmic calcein
fluorescence, rendering the signal mitochondrial-specific. Firstly,
we found that total calcein fluorescence load (i.e. in the absence
of CoCl2) was comparable between all the patient-derived LCLs
and WT cells (Fig. 4A). Interestingly, we found that WHS LCLs
from patient A(83) and D(78) specifically exhibited elevated
mitochondrial calcein fluorescence compared with WT LCLs and
those from patient C(355) (Fig. 4B). This is suggestive of the
mPTP favouring a predominantly closed state and/or insensitive
ability to transition between open and closed conformations in
resting mitochondria in A(83) and D(78) LCLs. These cell lines
both exhibited LETM1 haploinsufficiency and decreased
mitochondrial LETM1 levels compared with WT LCLs and those
of patient C(355) (Figs 1, 2).
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Fig. 3. Mitochondrial mass and intracellular [Ca2+] in WHS-patient LCLs. (A) Mean relative fluorescence of MitoTracker-Green in WHS LCLs is shown
relative to that of wild-type (WT) normal LCLs, the latter illustrated by the horizontal dashed line. Cells were treated with 250 nM MitoTracker-Green for 15
minutes and fluorescence quantified using the FACS Canto platform (FITC-A: area under the curve). All of the WHS LCLs, irrespective of LETM1 copy number,
exhibit a comparable level of MitoTracker-Green fluorescence compared with WT. Data represents the mean ± s.d. from three separate experiments.
(B) Calcium 1-AM profiles for the WHS LCLs. The profile for the wild-type (WT) normal LCLs is in blue. WHS LCLs with LETM1 haploinsufficiency are in green,
whereas those with normal LETM1 copy number are depicted in red. (C) Mean relative Calcium 1-AM levels in WHS LCLs is shown relative to that of wild-type
(WT) normal LCLs, the latter illustrated by the horizontal dashed line. Cells were treated with 10 μM Calcium 1-AM for 20 minutes and fluorescence analysed
(excitation/emission 506/531) on the FACS Canto platform. Both A(83) and D(78) LCLs exhibit an elevated level of Calcium 1-AM relative to WT LCLs and the
WHS LCLs C(355) and FN4367 (P<0.05, Student’s t-test). Both A(83) and D(78) exhibit LETM1 haploinsufficiency, whereas C(355) and FN4367 have normal
LETM1 copy number. Data represents the mean ± s.d. from three separate experiments (FITC-A: area under the curve). D
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Treatment of cells with a Ca2+ ionophore such as ionomycin induces
mitochondrial Ca2+ overload, typically resulting in mPTP opening and
consequent reduction of calcein retention. Treatment of WT LCLs and
LCLs from patient C(355) with ionomycin resulted in an ~60%
decrease in mitochondrial calcein fluorescence, consistent with mPTP
opening, as expected (Fig. 4C). In stark contrast, A(83) and D(78)
patient-derived LCLs exhibited only a modest 25-30% relative
reduction in mitochondrial calcein fluorescence under identical
treatment conditions (Fig. 4C). These results are consistent with a
[Ca2+]-insensitive mPTP adopting a predominantly closed
conformation in WHS-patient LCLs with LETM1 haploinsufficiency,
further indicative of altered mitochondrial-mediated [Ca2+] buffering
in this context. This cellular phenotype has not previously been
described in WHS-patient cells.
LETM1 haploinsufficiency in WHS is associated with
mitochondrial membrane hyperpolarisation: elevated ΔΨmito
The mitochondrial membrane potential (ΔΨmito) is exquisitely
sensitive to mitochondrial ion flux. In their identification of LETM1
as a mitochondrial Ca2+/H+ antiporter, Jiang and colleagues found
that siRNA-mediated silencing of Letm1 in Drosophila S2 cells
resulted in a modest although notable (~1.3-fold) increase in ΔΨmito
(Jiang et al., 2009). Whether only a 50% reduction in LETM1
expression as a consequence of LETM1 haploinsufficiency could
result in a similar effect upon ΔΨmito has not previously been
investigated. Considering our findings regarding intracellular [Ca2+]
and mPTP (Figs 3, 4), we examined ΔΨmito status in resting
mitochondria in LCLs from our WHS cohort. Using MitoTracker
Red-CMXRos fluorescence, we consistently found spontaneously
elevated ΔΨmito (~1.4- to 1.6-fold) in WHS-patient LCLs with
LETM1 haploinsufficiency [i.e. A(83), D(78), E(88)] compared with
those with normal LETM1 expression [i.e. C(355), FN4367] and
with WT LCLs (Fig. 4D). This suggests that LETM1
haploinsufficiency in the context of WHS is associated with
spontaneous hyperpolarisation of resting mitochondria. This
represents an additional novel mitochondrial phenotype associated
with WHS and, in the context of this cohort, an additional phenotype
segregating with seizure expression.
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Fig. 4. Mitochondrial transition pore (mPTP) dyamics and mitochondrial membrane polarization in WHS-patient LCLs. (A) Total cellular Calcein
fluorescence is comparable between WT LCLs and WHS patient and WHS-like patient LCLs irrespective of LETM1 copy number. Calcein fluorescence was
measured in the absence of CoCl2 and expressed as fold change relative to WT LCLs (a.u., arbitrary units). Data represents the mean ± s.d. from three separate
experiments (FITC-A: area under the curve). (B) Mitochondrial calcein fluorescence levels (a.u., arbitrary units) indicate that the WHS LCLs A(83) and D(78) both
exhibit elevated levels of mitochondrial calcein retention compared with WT LCLs and those of patient C(355). Here, calcein fluorescence is measured in the
presence of CoCl2, which quenches the cytoplasmic (i.e. non-mitochondrially derived) signal. Data represent the mean ± s.d. from three separate experiments
(FITC-A: area under the curve). (C) Mean relative level of mitochondrial calcein retention in WHS LCLs of differing LETM1 copy number compared with WT LCLs
in the absence (black bar) or presence (white bar) of the Ca2+ ionophore, ionomycin. Both WT and C(355) exhibit a near 60% drop in calcein retention following
ionomycin (500 nM) relative to CoCl2 treatment alone. This is in contrast to A(83) and D(78) LCLs, which only drop by about 20-30% under these conditions. This
is suggestive of an insensitive mPTP favouring a closed conformation conducive to mitochondrial calcein retention. Data represents the mean ± s.d. from at least
three separate experiments (FITC-A: area under the curve). (D) Mean relative fluorescence of MitoTracker-Red in WHS LCLs is shown relative to that of wild-
type (WT) normal LCLs, the latter illustrated by the horizontal dashed line. Cells were treated with 250 nM MitoTracker-Red for 15 minutes and fluorescence
quantified using the FACS Canto platform. WHS LCLs A(83), D(78) and E(88) exhibit elevated MitoTracker-Red fluorescence, suggestive of hyperpolarised
resting mitochondria (elevated ΔΨmito), compared with WT LCLs and those from patients C(355) and FN4367 (P<0.05, Student’s t-test). Data represent the mean
± s.d. from three separate experiments (PE-A: area under the curve). Control experiments, using depolarising and hyperpolarising treatments, are shown in
supplementary material Fig. S1A,B.
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LETM1 haploinsufficiency in WHS is associated with
elevated mitochondrial superoxide (O2
–) production
Mitochondrial dysfunction is often associated with elevated
superoxide (O2
–) leakage (Kang and Pervaiz, 2012; Pieczenik and
Neustadt, 2007). Using MitoTracker-SOX fluorescence as a direct
measure of mitochondrial [O2
–], we found a striking increase (~1.4-
to 1.6-fold) in mitochondrial ROS in WHS-patient LCLs with
LETM1 haploinsufficiency, specifically A(83), D(78) and E(88)
patient LCLs, in contrast to WHS-patient cells with normal LETM1
copy number [i.e. C(355), FN4367] and to WT LCLs (Fig. 5A,B).
In fact, the elevated level of mitochondrial O2
– production in these
LCLs was comparable to that of an LCL derived from a patient with
myoclonus epilepsy with ragged-red fibres (MERRF) (Fig. 5B).
MERFF is a primary mitochondrial disorder. Interestingly, elevated
mitochondrially derived O2
– was not associated with an overall
elevated level of intracellular ROS in these cells, as determined by
CellROX-Red fluorescence (Fig. 5C). These data further indicate
that LETM1 haploinsufficiency in the context of WHS is associated
with specific mitochondrial dysfunctions.
Our analysis of WHS-patient LCLs has shown that
haploinsufficiency of LETM1 is associated with reduced LETM1
expression within isolated mitochondria and this segregates with
elevated intracellular [Ca2+], an insensitive mPTP adopting a
predominantly closed conformation, spontaneously elevated ΔΨmito
indicative of hyperpolarized mitochondria, as well as elevated
mitochondrial ROS production in resting mitochondria. These
represent novel cellular phenotypes for WHS. Interestingly, these
phenotypes also seem to segregate with the WHS patients within our
small cohort who have presented with seizures. Mindful of the fact
that other genes are also deleted in our WHS lines and that other
regions within 4p16.3 might also contribute to seizure development
in this condition, we set out to establish whether reduced expression
of LETM1 alone could recapitulate some of the key mitochondrial
phenotypes that we have identified here.
Reduced LETM1 is associated with elevated ΔΨmito and
elevated mitochondrial O2
–
Using the mouse neuroblastoma cell line Neuro2A as a model
system, we investigated whether siRNA-mediated reduction of
Letm1 alone could recapitulate some of the novel mitochondrial
phenotypes we have described here in LETM1-haploinsufficient
WHS-patient LCLs. We carefully optimised our siRNA procedure
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Fig. 5. Mitochondrial [O2
–] and total cellular ROS levels in WHS-patient LCLs. (A) Representative fluorescence profiles following treatment of WT and
WHS-patient LCLs with MitoTracker-SOX (250 nM for 15 minutes) as obtained from the FACS Canto platform. Elevated levels of mitochondrial-derived ROS
(O2
–) are indicated by the black triangle. The WHS LCLs with LETM1 haploinsufficiency show marked peaks towards the right of each profile (elevated
fluorescence) compared with WT LCLs and those from the WHS patients with normal LETM1 copy number [C(355) and FN4367]. A control experiment using
thalidomide, a drug known to produce reactive oxygen species, is shown in supplementary material Fig. S1C. (B) Mean relative fluorescence of MitoTracker-
SOX in WHS LCLs is shown relative to that of wild-type (WT) normal LCLs, the latter illustrated by the horizontal dashed line. WHS LCLs A(83), D(78) and
E(88) exhibit elevated MitoTracker-SOX fluorescence indicative of elevated O2
– production from resting mitochondria, compared with WT LCLs (dashed line)
and those from patients C(355) and FN4367 (P<0.05, Student’s t-test). Furthermore, a MERRF (myoclonus epilepsy associate with ragged-red fibres) patient-
derived LCL also exhibited a similarly significantly elevated MitoTracker-SOX fluorescence to that of the LETM1/−WHS LCLs. Data represent the mean ± s.d.
from three separate experiments (PE-A: area under the curve). (C) Mean relative fluorescence of CellROX-Red in WHS LCLs is shown relative to that of wild-
type (WT) normal LCLs, the latter illustrated by the horizontal dashed line. CellROX-Red fluorescence is a measure of total cellular ROS. Pre-treatment of WT
LCLs with the oxidant tert-Butyl hydroperoxide (tBOOH; 100 μM, 1 hour) resulted in an ~fivefold increase in CellROX-Red mean fluorescence relative to
untreated WT LCLs. All of the WHS LCLs, irrespective of LETM1 copy number, exhibit a comparable level of CellROX-Red fluorescence compared with WT.
Data represent the mean ± s.d. from three separate experiments (PE-A: area under the curve).
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(by titration) so as to only obtain an ~50% reduction in Letm1 to
closer mimic the WHS-patient LCL situation. As shown in Fig. 6A,
siRNA-mediated reduction of Letm1 to ~50% of control-transfected
(Ctrl) Neuro2A cells resulted in elevated ΔΨmito (MitoTracker-Red)
and mitochondrial O2
– production (MitoTracker-SOX), whilst not
affecting mitochondrial mass (MitoTracker-Green) (Fig. 6B,C).
These phenotypes are identical to those identified here for WHS-
patient LCLs haploinsufficient for LETM1 (Fig. 3A; Fig. 4C; Fig.
5A,B).
To further reinforce the fact that the elevated levels of
mitochondrial O2
– observed under these conditions were directly
attributable to reduced LETM1 levels, we performed a similar
analysis, although in this case using the human T98G glioblastoma
line, with the additional element of complementation with an
siRNA-resistant cDNA encoding LETM1. The siRNA
oligonucleotide was designed to the 3′UTR of LETM1 and, as
expected, resulted in a significant reduction in LETM1, which was
also associated with elevated mitochondrial O2
– (MitoTracker-SOX)
(Fig. 6D,E). In fact, under these conditions we observed an over
threefold increase in mitochondrial O2
– production (Fig. 6E).
Importantly, co-transfection of the 3′UTR-directed oligo with the
siRNA-resistant cDNA was associated with the consequent
reduction in mitochondrial ROS (Fig. 6E). These data show that
modestly reduced expression of LETM1 alone can cause
mitochondrial dysfunction. Unfortunately, we were unable to
generate a viable and stable WHS-patient LCL stably transduced
with LETM1 from a lentivirus (CMV-driven pReceiver-Lv105
expression clone LP-W0230-Lv105-0200-S, Genecopoea).
In summary, using a panel of WHS and WHS-like patient LCLs
with differing sized deletions incorporating LETM1 or not, we show
that haploinsufficiency of LETM1 is associated with reduced
LETM1 expression and a series of mitochondrial phenotypes. These
include elevated intracellular [Ca2+], an insensitive mPTP and
hyperpolarized mitochondria (elevated ΔΨmito) with elevated
mitochondrial O2
– production. Many of these mitochondrial deficits
have been previously associated with seizures. In our patient cohort,
these mitochondrial phenotypes segregate with seizure presentation.
Our data strongly suggest that a 50% reduction in LETM1
541
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Fig. 6. Knockdown of LETM1 recapitulates mitochondrial phenotypes of WHS-patient LCLs with haploinsufficiency of LETM1. (A) Western blot
analysis of Letm1 expression following siRNA-mediated silencing of Letm1 in mouse Neuro2A cells. An ~50% reduction in Letm1 was observed 48 hours post-
transfection. Ctrl, control-transfected. The membrane was re-probed for α-tubulin to confirm loading. (B) Representative fluorescence profiles following siRNA-
mediated reduction of Letm1 to 50% in Neuro2A cells and incubation with MitoTracker-Red (upper panel) and MitoTracker-SOX (lower panel). The siRNA-
treated profile for each MitoTracker is shown in red. Ctrl, control-transfected. Elevated fluorescence for each MitoTracker is indicated by a rightward shift in the
profiles following siRNA of Letm1 relative to Ctrl. (C) Mean relative fluorescence of MitoTracker-Red, MitoTracker-Green and MitoTracker-SOX levels following
siRNA in Neuro2A cells is shown relative to that of control-transfected (Ctrl) cells, the latter illustrated by the horizontal dashed line. The siRNA-mediated
reduction of Letm1 to 50% results in elevated MitoTracker-Red and MitoTracker-SOX fluorescence specifically, not impacting upon MitoTracker-Green levels.
Therefore, siRNA of Letm1 is associated with increased hyperpolarisation (elevated ΔΨmito) and elevated O2– production from resting mitochondria under these
conditions, without impacting upon mitochondrial mass. Data represent the mean ± s.d. from three separate experiments (MitoT-Red and MitoT-Green; PE-A:
area under the curve; MitoT-Green: FITC-A: area under the curve). (D) Western blot analysis for LETM1 from human T98G glioblastoma cells following either
siRNA of LETM1 using a 3′UTR-directed oligonucleotide or transfection with a plasmid containing LETM1, or a combination of both as indicated. The
membrane was re-probed for MCM2 to confirm loading. (E) Mean relative fluorescence of MitoTracker-SOX in T98G cells is shown relative to that of control-
transfected cells (Ctrl), following silencing of LETM1 (siRNA), along with co-transfection with an siRNA-resistant LETM1 cDNA (siRNA + cDNA). Silencing of
LETM1 using a 3′UTR-directed oligonucleotide directed against the endogenous gene results in a marked increase in MitoTracker-SOX levels indicative of
elevated mitochondrial ROS production (Ctrl versus siRNA P<0.05, Student’s t-test). Co-transfection with an siRNA-resistant LETM1-encoding plasmid reduces
the level of MitoTracker-SOX fluorescence to that of control-transfected cells (Ctrl). Data represent the mean ± s.d. from three separate experiments (PE-A:
area under the curve).
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expression as a consequence of LETM1 haploinsufficiency in WHS
can result in overt mitochondrial phenotypes.
DISCUSSION
WHS is generally regarded as a multigenic condition with
haploinsufficiency of the critical regions thought to explain many of
the core clinical features, although other genes clearly have
additional contributions (Engbers et al., 2009; South et al., 2007;
South et al., 2008; Van Buggenhout et al., 2004). For example, we
recently identified delayed S-phase progression and impaired
chromatin remodelling in WHS-patient LCLs attributable to
haploinsufficiency of SLBP and/or WHSC2 (NELF-A); phenotypes
with implications for the maintenance of epigenetic memory,
expansion of stem cell niches, and possibly microcephaly and
growth retardation (Kerzendorfer et al., 2012). Assessing the
contribution of haploinsufficiency of a single gene towards a
specific phenotype or set of phenotypes characteristic of a
contiguous gene deletion disorder can be complex. This needs to be
considered in the context of variable expressivity, incomplete
penetrance or the revelation of recessive alleles and/or complex
positional effects (reviewed in Hart and O’Driscoll, 2013). Single-
gene contributions are usually based on the existence of patients
with rare atypical and/or very small deletions being placed in
context of the more commonly sized deletions. Additionally, in
some cases murine models might be available, enabling
interpretation of the pathomechanistic impact of impaired function
of a particular gene. For WHS, several mouse models for genes
within human somatic autosome (HSA) 4p16.3 have been used as
supportive evidence for the haploinsufficiency of certain genes in
underlying specific clinical features of the condition. Examples
include Whsc1 for cardiac and midline abnormalities, Fgfr3 and
Ctbp1 for skeletal abnormalities, and Fgfr3, Ctbp1, Tacc3 and
Hspx153 for growth retardation (Abrams and Jiao, 2009; Näf et al.,
2001; Nimura et al., 2009; Simon and Bergemann, 2008).
When considering seizures in WHS, the situation is highly
complex. The segregation of seizures with LETM1
haploinsufficiency does not seem to be absolute (Andersen et al.,
2013; South et al., 2008). There are a modest although growing
number of cases with sub-telomeric deletions not involving
LETM1 that have been reported with seizures, whereas,
conversely, there are also deletion cases incorporating LETM1 that
are reported to be seizure free (Andersen et al., 2013; Bayindir et
al., 2013; Engbers et al., 2009; Faravelli et al., 2007; Izumi et al.,
2010; Misceo et al., 2012; South et al., 2008; Van Buggenhout et
al., 2004). In fact, whether LETM1 haploinsufficiency plays any
role whatsoever in seizure development has been questioned by
some (Bayindir et al., 2013; Luo et al., 2011). Importantly, to our
knowledge, neither LETM1 expression nor functional
mitochondrial characterisation has been investigated in these
situations (Bayindir et al., 2013; Luo et al., 2011). Furthermore,
CTBP1 and/or CPLX1 haploinsufficiency, two genes telomeric to
LETM1, have also been proposed to possibly underlie seizures in
WHS, although, again, without any supportive, associative
functional cellular characterization in WHS-patient cell lines
(Misceo et al., 2012; Simon and Bergemann, 2008).
Attributing reduced LETM1 expression as the cause of or
contributing factor to seizures in WHS has evolved from a
combination of (i) cataloguing patients with different sized deletions
and variable seizure expression, (ii) realising LETM1’s
mitochondrial localisation and its role in ion transport, and (iii) the
overt mitochondrial morphological changes observed in
Saccharomyces cerevisiae, Drosophila, Caenorhabditis elegans and
even HeLa cells, when LETM1 levels were reduced (Dimmer et al.,
2008; Endele et al., 1999; Hasegawa and van der Bliek, 2007;
McQuibban et al., 2010; Nowikovsky et al., 2004; Tamai et al.,
2008). Furthermore, (iv) downregulation of CG4589, the LETM1
orthologue in Drosophila, also leads to reduced synaptic
neurotransmitter release (McQuibban et al., 2010).
Recently, two interesting murine-based models of reduced Letm1
expression have further strengthened the pathomechanistic link
between LETM1-induced mitochondrial dysfunction and seizures.
Zhang and colleagues showed that stereotaxic intra-hippocampal
injection of a Letm1-targeting shRNA lentivirus induced
mitochondrial swelling and decreased mitochondrial cytochrome b
expression in the brains of rats (Zhang et al., 2013). Furthermore,
this was associated with reduced onset latency, and increased
frequency and duration of pilocarpine-induced epilepsy (Zhang et
al., 2013). These authors also reported lower LETM1 expression in
the temporal neocortex of individuals with temporal lobe epilepsy
compared with normal individuals (Zhang et al., 2013). Jiang and
colleagues reported a gene-trap-based targeting of Letm1 in mice,
which resulted in early embryonic lethality for the homozygous
deletion and 50% loss of the heterozygotes before E13.5 (Jiang et
al., 2013). The surviving Letm1 heterozygotes exhibited impaired
brain-specific glucose metabolism and reduced ATP levels, as well
as increased kainic-acid-induced seizure activity (Jiang et al., 2013).
Although the precise role of LETM1 in mitochondrial ion
transport is still debated (i.e. its function as a Ca2+ antiporter
versus K+/H+ exchange), there is growing evidence to suggest that
reduced LETM1 expression can impact on different aspects of
mitochondrial function (Nowikovsky et al., 2012; Nowikovsky et
al., 2009). Altered mitochondrial function is strongly associated
with seizure development (Folbergrová and Kunz, 2012; Kang et
al., 2013). Indeed, several established mitochondrial disorders such
as Kearns-Sayre syndrome and MERRF are strongly seizure-prone
(Koopman et al., 2012). When considering LETM1
haploinsufficiency, the consequent chronic mitochondrial
hyperpolarisation in the context of elevated mitochondrial O2
–
production and mPTP dysfunction could conceivably have
catastrophic implications for normal neuronal function. Our work
describes for the first time a set of mitochondrial phenotypes in
WHS-patient-derived LCLs that also segregate with seizure
development in the small cohort examined. This is notable because
LCL C(355), which does not present with any of the aberrant
mitochondrial phenotypes identified here, has a deletion that
incorporates CTBP1 and CPLX1, yet this individual is seizure free
(Hannes et al., 2010). Furthermore, we can model some of the
mitochondrial phenotypes identified in the LCLs by manipulating
LETM1 expression in cell lines of neuronal (Neuro2A) and glial
(T98G) origin (Fig. 6). It would be fascinating to investigate the
mitochondrial phenotypes we have identified here in cells from
patients presenting with seizures in the context of normal LETM1
copy number. There is now growing evidence for a multigenic
basis for seizures in individuals with deletions within 4p16.3
(Andersen et al., 2013; Misceo et al., 2012; South et al., 2007).
This multigenic phenomenon is not without precedent in WHS.
For example, we have recently characterised a multigenic basis for
DNA replication and chromatin formation impairments in WHS
(Kerzendorfer et al., 2013; Kerzendorfer et al., 2012).
The mitochondrial phenotypes we have described substantially
build upon those already attributed to reduced LETM1 expression
(Jiang et al., 2009; Jiang et al., 2013; Nowikovsky et al., 2012). The
phenotypes described in our study are highly interdependent and
likely a consequence of LETM1’s fundamental role in mitochondrial
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ion transport. We found elevated intracellular [Ca2+] and a [Ca2+]-
insensitive mPTP in WHS LCLs with LETM1 haploinsufficiency.
Each of these could underlie or contribute to the elevated ΔΨmito and
elevated mitochondrial ROS we also observed in this context
(Brookes et al., 2004). Importantly, we have described these findings
in the clinically relevant setting of patient-derived cells.
Our work suggests that WHS-patient LCLs could serve as a
tractable model platform to investigate potential therapeutically
relevant routes into mitigating against the phenotypes that we have
catalogued, phenotypes that are likely relevant to seizures or
additional clinical features (Liu and Schubert, 2009). For example,
in some instances treatment with nigericin, an ionophore that
catalyses electroneutral K+/H+ exchange in mitochondria, has been
reported to reverse LETM1-dependent mitochondrial morphological
changes (Dimmer et al., 2008; Nowikovsky et al., 2004;
Nowikovsky et al., 2009). Nevertheless, we found that treatment of
WHS LCLs with nigericin (2 μM) for up to 24 hours had no impact
on mitochondrial O2
– levels (not shown).
We believe that our data provide supportive associative evidence
for a contribution of reduced LETM1 expression and consequent
mitochondrial dysfunction to the clinical presentation of WHS.
Wider implications of LETM1-dependent mitochondrial dysfunction
outside of seizures could include, for example, impacts upon optimal
motor and muscle function with relevance to hypotonia in WHS.
Furthermore, considering the high energy demands of the brain,
LETM1-dependent mitochondrial dysfunction could impact upon
other aspects of optimal neuronal function that might be relevant to
intellectual disability herein. Collectively, our findings underscore
the dramatic and newly identified impacts upon mitochondrial
function that a modest 50% reduction in LETM1 expression has in
WHS-patient-derived LCLs.
MATERIALS AND METHODS
Cell culture
Lymphoblastoid cell lines (LCLs) were cultured at 37°C in humidified
incubators with 5% CO2 in RPMI 1640 supplemented with 2 mM L-
glutamine, 500 U/ml penicillin, 50 μg/ml streptomycin and 15% fetal calf
serum. The MERFF (myoclonus epilepsy associated with ragged-red fibres)
LCL was obtained from the Coriell Cell Repository (Camden, NJ, USA).
The line, GM11907, has a mutant tRNA-Lys, A>G transition at mtDNA
nucleotide pair 8344/WT. Neuro-2A (N2A) cells were maintained in
Dulbecco’s modified Eagle medium supplemented with 2 mM L-glutamine,
500 U/ml penicillin, 50 μg/ml streptomycin and 10% fetal bovine serum.
T98G human glioblastoma cells were cultured in minimum essential
medium supplemented with 10% fetal bovine serum, 1% non-essential
amino acid (NEAA) and 1% sodium pyruvate, 2 mM L-glutamine, 500
U/ml penicillin and 50 μg/ml streptomycin.
Antibodies
Anti-α-tubulin (T1568) was obtained from Sigma-Aldrich (Poole, Dorset,
UK). Anti-hexokinase 1 (2024, C25C4) was obtained from Cell Signaling
Technology (NEB, Hitchin, Hertfordshire, UK). Anti-β-tubulin (sc-9104),
anti-MCM2 (sc-9839) and anti-LETM1 (sc-271232) were from Santa Cruz
(Insight Biotec Ltd, Wembley, Middlesex, UK).
Extract preparation
Urea-based whole cell extracts (WCEs)
Cell pellets were washed in PBS then lysed in 50-100 μl of urea-based lysis
buffer (9 M urea, 50 mM Tris-HCl at pH 7.5 and 10 mM 2-β-
mercaptoethanol), followed by a 12-second sonication at 30% amplitude.
Protein concentration was determined using the Bradford Assay. Samples
were then stored at −20°C or immediately boiled in 2× SDS-loading buffer
(5% SDS, 10% glycerol, 10% 2-β-mercaptoethanol, 125 mM Tris-HCl, pH
6.8 and 0.2% bromophenol blue) and loaded onto SDS-PAGE gels.
Mitochondrial isolation and extracts
Mitochondrial isolation was performed using the Miltenyi Biotec (Bisley,
Surrey, UK) Mitochondrial Isolation Kit (Cat. no.: 130-094-532) according
to the manufacturer’s instructions with slight modification as indicated. 107
cells were lysed using the lysis buffer provided and homogenised using a
glass mini-strokes homogenizer, with 10-15 strokes per sample, on ice.
Lysate was incubated with anti-TOM22 magnetic microbeads for 1 hour at
4°C with gentle shaking. An LS column was placed in the magnetic field of
a QuadroMACS separation unit and the lysate was then applied to the LS
column. Once the lysate had run through, the column was washed 3× with
the supplied separation buffer before being removed from the magnetic field
and placed onto a 1 ml collection tube. The magnetically retained
mitochondria were eluted in 1 ml of the supplied separation buffer and
subsequently centrifuged at 13,000 g for 2 minutes to pellet mitochondria.
The mitochondrial pellet was resuspended in 60 μl of urea lysis buffer and
sonicated for 15 seconds at 30% amplitude. 0.1-2 μl (for LETM1) or 8 μl
(for hexokinase 1) of mitochondrial extract was then immediately boiled in
2× SDS-loading buffer (5% SDS, 10% glycerol, 10% 2-β-mercaptoethanol,
125 mM Tris-HCl, pH 6.8 and 0.2% bromophenol blue) and loaded onto
SDS-PAGE gels.
Mitochondrial transition pore (mPTP) analysis
The mPTP kit (Life Technologies, Paisley, UK, Cat no.: M34153) was used
according to the manufacturer’s instructions. LCLs were re-suspended in
pre-warmed Hanks Balanced Salt Solution with Ca2+ at a final concentration
of 1×106 cells/ml. 3×1 ml aliquots were prepared per cell line (tube 1,2,3).
10 nM calcein AM was added to each tube, 400 μM CoCl2 was added to
tubes 2 and 3 and 500 nM ionomycin was added to tube 3. Samples were
incubated for 15 minutes at 37°C, protected from light. Cells were pelleted
by centrifugation, re-suspended in 500 μl PBS and filtered into FACS Falcon
tubes (Becton Dickinson, Oxford, UK) for flow cytometry analysis using a
Becton Dickinson (BD) FACS Canto. Samples were analysed using 488 nm
excitation and emission filters appropriate for fluorescein with BD FACS
Diva software. A sample without added reagents was used for instrument set
up.
MitoTracker probes
LCLs were pelleted by centrifugation and resuspended in pre-warmed
growth medium containing 250 nM MitoTracker-Red (M7512) or
MitoTracker-Green (M7514) or MitoTracker-SOX (M36008), all of which
were obtained from Molecular Probes, Life Technologies (Invitrogen,
Paisley, UK). Cells were incubated for 15 minutes under growth conditions,
protected from light. After treatment, LCLs were washed once in 1× PBS.
Cells were then re-suspended in 500 μl PBS and filtered into FACS Falcon
tubes for immediate flow cytometry analysis. Adherent cells (i.e. T98G and
Neuro2A) were incubated with 250 nM MitoTracker probe for 15 minutes
and washed once in 1× PBS. Cells were then trypsinised or detached using
a cell scraper and filtered into FACS Falcon tubes for flow cytometry
analysis. All data was collected using a BD FACS Canto Flow Cytometer
(Oxford, UK) and analysed with BD FACS Diva software.
Total intracellular ROS determination
Cells were treated with CellROX-Red (Life Technologies, Paisley, UK, Cat
no.: C10422) at a final concentration of 5 μM and incubated for 30 minutes
at 37°C. The medium was then removed and cells were washed three times
with PBS. Cells were then filtered into BD FACS Falcon tubes and analysed
by flow cytometry using 640/665 nm excitation/emission filters. Data was
collected using a BD FACS Canto flow cytometer (Oxford, UK) and
analysed with the BD FACS Diva software.
Intracellular calcium determination
LCLs were incubated with 10 μM Calcium 1-AM probe (Life Technologies,
Paisley, UK, Cat. no.: C3012) for 20 minutes under normal growth
conditions. Cells were washed then re-suspended in 500 μl PBS and filtered
into BD FACS Falcon tubes (Oxford, UK). Data was collected using a BD
FACS Canto and subsequent analysis was performed using the BD FACS
Diva software with 506/531 excitation/emission filters.
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siRNA knockdowns
Mouse Letm1 (Neuro2A cell line)
ON-TARGETplus SMARTpool siRNAs against Letm1 (L-049478-01-005,
mouse) were obtained from Thermo Fisher Scientific (Loughborough, UK)
and re-suspended in DPEC-treated water to a final concentration of 5 nmol.
Transfections were performed using 1×5 μl siRNA against Letm1 in the
presence of 5 μl MetafectenePro (Cambio, Cambridge, UK). Cells were
harvested 48 hours post-transfection. Sense target sequences are: (1) 5′-
AGGUAGACAACAAGGCGAA-3′; (2) 5′-CCAACAACUUCCUGC -
GUUU-3′; (3) 5′-CUAAAUAGUCGGGUGACAUA-3′; (4) 5′-CUGC -
CUAAUUCAUGAGUAA-3′.
Human LETM1 (T98G cell line)
Stealth siRNAs (Life Technologies, Paisley, UK) were designed against the
3′UTR region of human LETM1 using the BLOCK-ITTM RNAi designer
(Invitrogen Life Technologies, Paisley, UK). Oligos were re-suspended in 1
ml of DPEC-treated water to a final concentration of 20 nmol. Transfections
were performed with 1× 5 μl siRNA against LETM1 in the presence of 5 μl
MetafectenePro (Cambio, Cambridge, UK). Cells were harvested 24 hours
post-transfection. LETM1 3′UTR target sequence is: 5′-CCACAG -
AAUCGUGUCUGGAUCCACA-3′.
LETM1 overexpression
T98G human glioblastoma cells were transfected with 2 μg plasmid
encoding LETM1 (pCMV6-XL4) purchased from Origene, in the presence
of 5 μl MetafectenePro (Biontex) under normal growth conditions. Cells
were harvested 24 hours post-transfection and prepared for flow cytometry
or western blot analysis as described above.
LETM1 complementation
T98G cells were transfected with 5 μl siRNA against LETM1 in the presence
of 5 μl MetafectenePro (Biontex) + 2 μg of LETM1-expression vector. The
vector, pCMV6-XL4 containing human LETM1 (NM_012318), was
obtained from Origene (Insight Biotec Ltd, Wembley, Middlesex, UK, Cat.
no.: sc115448). At 24 hours post-transfection, cells were incubated with 250
nM MitoSOX for 15 minutes and processed as described above.
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